Bioequivalence and Bioavailability Forum 15:58 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Regulators view of HVD drugs [Regulatives / Guidelines]

posted by DavidManteigas - Portugal, 2017-05-16 12:41  - Posting: # 17357
Views: 9,183

Hi Helmut,

For the sake of curiosity, in your opinion should a regulator approve a generic submited as "highly variable" although all the previous trials reported low CV's? Technically, the criteria are well defined and no objection should be raised in principle. However, should a study that reports an high variation, when all the previous information reports otherwise, be considered scientifically sound for the demonstration of bioequivalence? Ideally, regulators would publish in their product-specific guidelines which compounds could be considered "highly variable"...

Regards,
David

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,606 posts in 3,959 threads, 1,208 registered users;
online 17 (1 registered, 16 guests [including 14 identified bots]).

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed